+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR T-cell Therapy: Global Strategic Business Report

  • PDF Icon

    Report

  • 179 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5139742

Quick Summary:

In the rapidly evolving and highly lucrative landscape of the global CAR T-cell Therapy market, staying abreast of the latest trends and industry developments is crucial for sustained growth. Our comprehensive Market Research Report, meticulously prepared by industry experts, offers deep insights into this burgeoning $9.6 billion field, providing you with competitive knowledge to optimize your strategic planning and decision-making.

This report conducts an in-depth analysis on a range of key metrics, including anticipated growth rates, key geographical markets, and a snapshot of significant competitors. Inclusive of unique market presence data across multiple geographies, it affords a detailed view into the industry's terrain. Moreover, subscribers will benefit from online interactive peer-to-peer collaborative bespoke updates, access to a robust digital research platform, and complimentary updates for one year, securing a real-time tactical advantage in this dynamic field.

Global CAR T-cell Therapy Market to Reach $9.6 Billion by 2030

The global market for CAR T-cell Therapy estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$9.6 Billion by 2030, growing at a CAGR of 21.9% over the analysis period 2022-2030. DLBCL, one of the segments analyzed in the report, is projected to record 18.7% CAGR and reach US$4.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ALL segment is readjusted to a revised 25.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $610.5 Million, While China is Forecast to Grow at 21.4% CAGR

The CAR T-cell Therapy market in the U.S. is estimated at US$610.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.9% and 18.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.

Select Competitors (Total 12 Featured) -

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for CAR T-cell Therapy

What is the estimated value of the Global Market for CAR T-cell Therapy?

The Global Market for CAR T-cell Therapy was estimated to be valued at $2 Billion in 2022.

What is the growth rate of the Global Market for CAR T-cell Therapy?

The growth rate of the Global Market for CAR T-cell Therapy is 21.7%, with an estimated value of $9.6 Billion by 2030.

What is the forecasted size of the Global Market for CAR T-cell Therapy?

The Global Market for CAR T-cell Therapy is estimated to be worth $9.6 Billion by 2030.

Who are the key companies in the Global Market for CAR T-cell Therapy?

Key companies in the Global Market for CAR T-cell Therapy include bluebird bio, Inc., CARsgen Therapeutics, Celgene Corporation, Gilead Sciences, Inc. and Novartis AG.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • CAR T-cell Therapy - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World CAR T-cell Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 3: World 8-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for DLBCL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World 8-Year Perspective for DLBCL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 6: World Recent Past, Current & Future Analysis for ALL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 7: World 8-Year Perspective for ALL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for MM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 9: World 8-Year Perspective for MM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for CLL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World 8-Year Perspective for CLL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 12: World Recent Past, Current & Future Analysis for FL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 13: World 8-Year Perspective for FL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 15: USA 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
CANADA
  • Table 16: Canada Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 17: Canada 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
JAPAN
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 18: Japan Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 19: Japan 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
CHINA
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 20: China Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: China 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
EUROPE
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 22: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 23: Europe 8-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
  • Table 24: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 25: Europe 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
FRANCE
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 26: France Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: France 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
GERMANY
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 28: Germany Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 29: Germany 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
ITALY
  • Table 30: Italy Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 31: Italy 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
UNITED KINGDOM
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 32: UK Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: UK 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
REST OF EUROPE
  • Table 34: Rest of Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 35: Rest of Europe 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
ASIA-PACIFIC
  • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 36: Asia-Pacific Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 37: Asia-Pacific 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
REST OF WORLD
  • Table 38: Rest of World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: Rest of World 8-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • bluebird bio, Inc.
  • CARsgen Therapeutics
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG